x POMALYST® (pomalidomide) is a thalidomide analogue indicated, in combination with dexamethasone, for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.

See other indications for POMALYST:

This website is intended for U.S. Healthcare Professionals.

This website is best viewed
using the horizontal display
on your tablet device.

This website is best viewed
using the vertical display
on your mobile device.

Resources for you and your patients.

Bristol Myers Squibb is dedicated to helping your patients start and continue an appropriate treatment with POMALYST® (pomalidomide) until disease progression or unacceptable toxicity.

Resources and tools for HCPs.

View HCP Resources

Help patients and caregivers with the information they need.

View Patient Resources

POMALYST is available only through a restricted distribution program called the POMALYST REMS® program.


Nurses: tools, resources, and information designed for you and your patients.

View Nurses Page

POMALYST is available only through a select network of specialty pharmacies.

View Specialty Pharmacy Network

Reference: 1. POMALYST [package insert]. Summit, NJ: Celgene Corp.

Get the resources and tools you need to
learn more about POMALYST.

View HCP Resources